Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ethinylestradiol, Norgestimate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Lizinna 250 microgram/35 microgram Tablets
Norgestimate/ethinylestradiol
Lizinna is a combined hormonal contraceptive pill ('the Pill'). You take it to stop getting pregnant. This contraceptive contains two types of female sex hormones, oestrogen and progestogen. These hormones prevent an egg being released from your ovaries so you cannot get pregnant. Also, Lizinna makes the fluid (mucus) in your cervix thicker which makes it more difficult for sperm to enter the womb. Lizinna is a 21-day Pill – you take one each day for 21 days, followed by 7 days when you take no pills. The benefits of taking the Pill include:
e Lizinna
928776
General notes Before you start using Lizinna you should read the information on blood clots in section 2.1. It is particularly important to read the symptoms of a blood clot – see Section 2.1 'The Pill and blood clots'. It is important that you understand the benefits and risks of taking Lizinna before you start taking it, or when deciding whether to carry on taking it. Although Lizinna is suitable for most healthy women it is not suitable for everyone. →Tell your doctor if you have any of the illnesses or risk factors mentioned in this leaflet. Before you start taking the Pill
What could you be suffering from? Deep vein thrombosis (DVT) (blood clot in the large vein of the leg)
symptoms most commonly in one eye:
Retinal vein thrombosis (blood clot in the eye)
Pulmonary embolism (PE) (blood clot in the lungs)
Heart attack
About 5-7 out of 10,000 women
Factors that increase your risk of a blood clot in a vein The risk of a blood clot with Lizinna is small but some conditions will increase the risk. Your risk is higher:
2.3. Lizinna should not be taken by some women
2.6. Taking Lizinna with food and drink
You should not take Lizinna if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate. →Tell your doctor or family planning nurse if you have any medical problems or illnesses. Do not take Lizinna if any of the following applies to you:
There are no special instructions about food and drink while on Lizinna.
2.4. Warnings and precautions When should you contact your doctor? Seek urgent medical attention
2.7. Pregnancy and breast-feeding Do not start to use Lizinna if you are pregnant. If you think you might be pregnant while taking Lizinna, do a pregnancy test to confirm that you are before you stop taking it. If you are breast-feeding, your doctor or family planning nurse may advise you not to take Lizinna. Talk to them about alternative contraception. Breast-feeding may not stop you getting pregnant. 2.8. Driving and using machines Lizinna has no known effect on the ability to drive or use machines. 2.9. Lizinna contains lactose and sodium If you have been told by your doctor that you have intolerance to some sugars contact your doctor before using Lizinna. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Lizinna 3.1. How to take it To prevent pregnancy, always take Lizinna as described below. Check with your doctor or family planning nurse if you are not sure. Take Lizinna every day for 21 days Lizinna comes in a strip of 21 pills, each marked with a day of the week.
2.5. Other medicines and Lizinna If you ever need to take another medicine at the same time as being on the Pill, always tell your doctor, pharmacist or dentist that you're taking Lizinna. Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives. Some medicines can stop Lizinna from working properly – for example:
Two or more pills
One pill
away, and further pills as usual. This may mean taking two pills in one day.
usual 7-day break before starting the next strip.
Fewer than 7 pills left in the pack
If you have missed any of the pills in a strip, and you do not bleed in the first pill-free break, you may be pregnant. Contact your doctor or family planning clinic, or do a pregnancy test yourself.
If you start a new strip of pills late, or make your 'week off' longer than eight days, you may not be protected from pregnancy. If you had sex in the last seven days, ask your doctor, family planning nurse or pharmacist for advice. You may need to consider emergency contraception. You should also use extra contraception, such as a condom, for seven days. 3.4. A lost pill If you lose a pill, just take a pill from a spare strip. Then take all the other pills from your current strip as usual. You can then keep the opened spare strip in case you lose any more pills. 3.5. If you are sick or have diarrhoea If you are sick or have very bad diarrhoea, your body may not get its usual dose of hormones from that pill. If you have been sick within 2 hours of taking Lizinna, just take a pill from a spare strip. Carry on taking your pills as normal if you can. You won't need to use extra contraception. If you are still sick or have diarrhoea for more than 1 day, follow the instructions for a missed pill – see section 3.3, A missed pill. →Talk to your doctor if your stomach upset carries on or gets worse. He or she may recommend another form of contraception. 3.6. Missed a period – could you be pregnant? Occasionally, you may miss a withdrawal bleed. This could mean that you are pregnant, but that is very unlikely if you have taken your pills correctly. Start your next strip at the normal time. If you think that you might have put yourself at risk of pregnancy (for example, by missing pills or taking other medicines), or if you miss a second bleed, you should do a pregnancy test. You can buy these from the chemist or get a free test at your family planning clinic or doctor's surgery. If you are pregnant, stop taking Lizinna and see your doctor. 3.7. Taking more than one pill should not cause harm It is unlikely that taking more than one pill will do you any harm, but you may feel sick, vomit or have some vaginal bleeding. Talk to your doctor if you have any of these symptoms. 3.8. You can delay a period If you want to delay having a period, finish the strip of pills you are taking. Start the next strip the next day without a break. Pill taking should then continue as usual. When you use the second strip, you may have some unexpected bleeding or spotting on the days that you take the pill, but don't worry. Take the next strip after the usual 7 day break even if you are still bleeding or spotting. 3.9. When you want to get pregnant If you are planning a baby, it is best to use another method of contraception after stopping Lizinna until you have had a proper period. Your doctor or midwife relies on the date of your last natural period to tell you when your baby is due. The Pill may reduce the levels of folic acid in the blood. Talk to your doctor, nurse or pharmacist as this could be important if you get pregnant straight after stopping the Pill.
4.2. Other possible side effects – tell your doctor Very common side effects (affects more than 1 in 10 patients)
This leaflet was last revised in April 2025
928776-01
MPL13958 – P1.1
Artwork for: Morningside Pharmaceuticals Ltd Product name: Lizinna 250mcg/ 35mcg tablets Size: 21 tablets PL/PA no: PL 20117/0220 Type: Leaflet Artwork dimensions: 860mm x 430mm Reason for request: Type IAin bulk submission (comma, alpha) Version no: 1.1 Date of revision: 11.5.26 Colours: As swatches Font(s): Nimbus Sans A/W software: Indesign CC
Black
Lizinna
Like all medicines, this medicine can cause side effects, although not everybody gets them. →Tell your doctor, pharmacist or family planning nurse if you get any side effect particularly if they are severe and persistent, or you have any change in your health which you think may be due to Lizinna.
Keep this medicines out of the sight and reach of children. Do not use Lizinna after the expiry date shown on the strip. The expiry date refers to the last day of that month. Store in the original package to protect from light. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
4.1. Serious side effects – see a doctor straight away
Contact a doctor immediately if you experience any of the following symptoms of angioedema: swollen face, tongue and/or throat and/or difficulty swallowing or hives potentially with difficulty breathing (see also section "Warnings and precautions"). Harmful blood clots in a vein or artery (frequency not known) for example:
What Lizinna contains
Lizinna 250 microgram /35 microgram Tablets comes as tablet containing 250mcg / 35mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Lizinna 250 microgram /35 microgram Tablets is ethinylestradiol, norgestimate.
This leaflet reproduces the patient information leaflet approved for Lizinna 250 microgram /35 microgram Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Contraception and the recognised indications for such oestrogen/progestogen combinations.
The decision to prescribe Lizinna should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lizinna compares with other Combined Hormonal Contraceptives (CHCs) (see sections 4.3 and 4.4).
For oral administration.
Adults
How to take Lizinna
One tablet is taken daily at the same time (preferably in the evening) without interruption for 21 days, followed by a break of 7 tablet-free days. Each subsequent pack is started after the 7 tablet-free days have elapsed. Additional contraceptive precautions are not then required. During the tablet-free period, bleeding can be expected, usually beginning 2 to 4 days after the last tablet.
Starting treatment
It is preferable that tablet intake from the first pack is started up to and including day 5 of menstruation in which case no extra contraceptive precautions are necessary.
Lizinna can be started at any other time, if pregnancy can reasonably be excluded. In this case additional contraceptive precautions must be taken for the first 7 days of tablet taking
Switching from another contraceptive
Hormonal methods: Lizinna can be started immediately if the patient has been using the current hormonal method consistently and correctly, or if pregnancy can reasonably be excluded. There is no need to wait for the next menstruation. Additional contraceptive precautions are not required.
Non-hormonal methods: If Lizinna is started after the first 5 days of menstruation, additional contraceptive precautions are required for the next 7 days.
Post-partum administration
Following a vaginal delivery, oral contraceptive administration to non-breast-feeding mothers can be started 21 days post-partum provided the patient is fully ambulant and there are no puerperal complications. No additional contraceptive precautions are required. If post-partum administration begins more than 21 days after delivery, additional contraceptive precautions are required for the first 7 days of pill-taking.
If intercourse has taken place post-partum, oral contraceptive use should be delayed until the first day of the first menstrual period.
For information on breast-feeding mothers, see section 4.6.
Use after Abortion or Miscarriage
After an abortion or miscarriage that occurs prior to 24 weeks gestation, oral contraceptives can be started immediately. An additional method of contraception is not needed.
After an induced or spontaneous abortion that occurs at or after 24 weeks gestation, hormonal contraceptives may be started either on Day 21 post-abortion or on the first day of the first spontaneous menstruation, whichever comes first. No additional contraceptive precautions are required.
To skip a period
To skip a period, a new pack of Lizinna should be started on the day after finishing the current pack (the patient skips the tablet-free days). Tablet-taking should be continued in the usual way.
During the use of the second pack she may experience slight spotting or break-through bleeding but contraceptive protection will not be diminished provided there are no tablet omissions.
The next pack of Lizinna is started after the usual 7 tablet-free days, regardless of whether the period has completely finished or not.
Reduced reliability
When Lizinna is taken according to the directions for use, the occurrence of pregnancy is highly unlikely. However, the reliability of oral contraceptives may be reduced under the following circumstances:
(i) Missed tablets
If the patient forgets to take one tablet or if a new strip is started one day late, she should take it as soon as she remembers and take the next one at the normal time. This may mean that two tablets are taken in one day. No additional contraceptive precautions are required. If more than one tablet is missed or if a new strip is started more than one day late, she should take the last missed tablet as soon as she remembers but leave the other missed tablets in the strip. She should continue to take the rest of the strip as usual but must use extra precautions (e.g. condom, diaphragm, plus spermicide) for the next 7 days.
If the tablets are missed:
• In week 1
If unprotected sex has taken place, the use of emergency contraception should be considered. The usual 7-day break can be left before starting the next strip.
• In week 2
The usual 7-day break can be left before starting the next strip.
• In week 3
When the strip is finished the next strip should be started the next day without a break. If withdrawal bleeding does not occur at the end of the second strip, a pregnancy test should be performed.
(ii) Vomiting or diarrhoea
If a patient vomits within two hours of taking a tablet she should take another tablet from a spare strip.
If severe vomiting or diarrhoea continues for more than one day, she should follow the procedure for missed tablets (and continue taking the tablets if she can).
Elderly:
Use of this product is not indicated in post-menopausal women.
Children:
Use of this product before menarche is not indicated.
• Presence or risk of venous thromboembolism (VTE)
o Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE])
o Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency (see section 4.4)
o Major surgery with prolonged immobilisation (see section 4.4)
o A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4)
• Presence or risk of arterial thromboembolism (ATE)
o Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)
o Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA)
o Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant)
o History of migraine with focal neurological symptoms
o A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
- diabetes mellitus with vascular symptoms
- severe hypertension
- severe dyslipoproteinaemia
• Acute or chronic liver disease, including hepatitis (viral or non-viral) or severe cirrhosis, or a history of these conditions until at least 3 months after abnormal liver function tests have returned to normal; hepatic adenomas or carcinomas.
• Known or suspected carcinoma of the breast.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Should any of these conditions occur for the first time during use of Lizinna, the tablets should be discontinued immediately.
Lizinna is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, medicinal products containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
Warnings
If any of the conditions/risk factors mentioned below is present, the suitability of Lizinna should be discussed with the woman.
In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Lizinna should be discontinued.
Exclude likelihood of pregnancy before starting treatment.
Undiagnosed vaginal bleeding should be investigated further.
Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.
Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.
Medical examination/consultation
Prior to the initiation or reinstitution of Lizinna a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contraindications (see section 4.3) and warnings (see section 4.4).
It is important to draw a woman's attention to the information on venous and arterial thrombosis, including the risk of Lizinna compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.
The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given.
The frequency and nature of examinations should be based upon established practice guidelines and should be adapted to the individual woman.
Women should be advised that oral contraceptives DO NOT protect against HIV infections (AIDS) or any other sexually transmitted disease.
Conditions requiring supervision
- The theoretical or proven risks usually outweigh the advantages of using Combined Oral Contraceptives (COCs) in the conditions listed below. Consequently the decision to prescribe the COC must be made with specialist clinical judgement.
- Breast feeding (see section 4.6)
- Increased risk of venous thromboembolic disorders (See section 4.3 and “Circulatory disorders” below)
- Adequately controlled hypertension (persistently elevated baseline systolic values 140-159 mmHg or diastolic values 90-94 mmHg)
- Obesity (BMI ≥ 35kg/m2)
- History of cholestasis (related to COCs), current or medically treated gall bladder disease, porphyria
- History of breast cancer, 5 years disease-free.
Circulatory disorders
Risk of Venous Thromboembolism (VTE)
The use of any CHCs increases the risk of venous thromboembolism (VTE) compared with no use. Products that contain levonorgestrel, norgestimate (including Lizinna) or norethisterone are associated with the lowest risk of VTE. The decision to use Lizinna should be taken after a discussion with the woman to ensure she understands the risk of VTE with Lizinna, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.
In women who do not use a CHC and are not pregnant, about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).
It is estimated that out of 10,000 women who use a CHC that contains levonorgestrel, about 6 will develop a VTE in a year.
Current evidence suggests that the risk of VTE with use of norgestimate-containing CHCs is similar to the risk with levonorgestrel-containing CHCs.
This number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.
VTE may be fatal in 1-2% of cases.
Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.
Risk factors for VTE
The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).
Lizinna is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors – in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).
Table: Risk factors for VTE
Risk factor
Comment
Obesity (body mass index over 30kg/m2)
Risk increases substantially as BMI rises.
Particularly important to consider if other risk factors also present.
Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma
Note: temporary immobilisation including air travel >4 hours can also be a risk factor for VTE, particularly in women with other risk factors
In these situations it is advisable to discontinue use of the Pill (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.
Antithrombotic treatment should be considered if Lizinna has not been discontinued in advance.
Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50)
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.
Other medical conditions associated with VTE
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.
Increasing age
Particularly above 35 years old.
There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.
The increased risk of thromboembolism in pregnancy, and particularly the 6 week period of the puerperium, must be considered (for information on “Pregnancy and lactation” see section 4.6).
Symptoms of VTE (deep vein thrombosis and pulmonary embolism)
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
• Symptoms of deep vein thrombosis (DVT) can include:
o unilateral swelling of the leg and/or foot or along a vein in the leg
o pain or tenderness in the leg which may be felt only when standing or walking
o increased warmth in the affected leg; red or discoloured skin on the leg.
• Symptoms of pulmonary embolism (PE) can include:
o sudden onset of unexplained shortness of breath or rapid breathing
o sudden coughing which may be associated with haemoptysis
o sharp chest pain
o severe light headedness or dizziness
o rapid or irregular heartbeat.
Some of these symptoms (e.g. shortness of breath, coughing) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).
Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discolouration of an extremity.
If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.
Risk of arterial thromboembolism (ATE)
Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (e.g. myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.
Risk factors for ATE
The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Lizinna is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).
Table: Risk factors for ATE
Risk factor
Comment
Increasing age
Particularly above 35 years old.
Smoking
Women should be advised not to smoke if they wish to use a CHC. Women over 35 years old who continue to smoke should be strongly advised to use a different method of contraception.
Hypertension
Obesity (body mass index over 30kg/m2)
Risk increases substantially as BMI increases.
Particularly important in women with additional risk factors.
Positive family history (arterial thromboembolism ever in a sibling or parent especially at a relatively early age e.g. below 50 years old).
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.
Migraine
An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.
Other medical conditions associated with adverse vascular events
Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.
Symptoms of ATE
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
• Symptoms of a cerebrovascular accident can include:
o sudden numbness or weakness of the face, arm or leg, especially on one side of the body
o sudden trouble walking, dizziness, loss of balance or coordination
o sudden confusion, trouble speaking or understanding
o sudden trouble seeing in one or both eyes
o sudden, severe or prolonged headache with no known cause
o loss of consciousness or fainting with or without seizure.
Temporary symptoms suggest the event is a transient ischaemic attack (TIA).
• Symptoms of myocardial infarction (MI) can include:
o pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone
o discomfort radiating to the back, jaw, throat, arm, stomach
o feeling of being full, having indigestion or choking
o sweating, nausea, vomiting or dizziness
o extreme weakness, anxiety, or shortness of breath
o rapid or irregular heartbeats.
Hepatic adenomas
Malignant hepatic tumours have been reported on rare occasions in long-term users of oral contraceptives. Benign hepatic tumours have also been associated with oral contraceptive usage. A hepatic tumour should be considered in the differential diagnosis when upper abdominal pain, enlarged liver or signs of intra-abdominal haemorrhage occur. In isolated cases, life-threatening intra-abdominal haemorrhage may occur.
Breast cancer
A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last 10 years are more likely to be localised to the breast than those in women who never used COCs.
Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).
The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by 10 years there appears to be no excess.
The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).
Cervical cancer
The most important risk factor for cervical cancer is persistent Human Papilloma Virus (HPV) infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.g. cervical screening and sexual behaviour including use of barrier contraceptives.
There is some theoretical concern that COCs enhance progression of Cervical Intraepithelial Neoplasia (CIN) to invasive disease. For women with diagnosed cervical cancer, COCs may be used whilst awaiting treatment.
Other tumours
Numerous epidemiological studies have been reported on the risk of ovarian and endometrial cancer in women using COCs. The evidence is clear that COCs offer substantial protection against both ovarian and endometrial cancer.
Bleeding irregularities
Breakthrough bleeding, spotting and/or absence of withdrawal flow may be encountered in patients on oral contraceptives, especially during the first three months of use.
If bleeding irregularities persist beyond three cycles or occur after previously regular cycles, non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy.
Some woman may experience post-Pill amenorrhoea or oligomenorrhoea, especially when such a condition was pre-existing.
Laboratory tests
In the literature, at least a hundred different laboratory test parameters have been reported to be possibly influenced by oral contraceptive use, predominantly by the oestrogenic component. Among these are: biochemical parameters of the liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins and lipid/lipoprotein fractions and parameters of coagulation and fibrinolysis.
Other conditions
In the following conditions the benefit of oral contraception generally outweighs the theoretical or known risk. However, they may need to be considered before prescribing to individual patients:
• Known hyperlipidaemias. A small proportion of women will have persistent hypertriglyceridemia while on the Pill. Changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. However, routine screening of women with hypertriglyceridaemia is not considered appropriate. Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.
• Diabetes without vascular involvement (although all patients with diabetes are at increased risk of arterial disease).
• Decreased glucose tolerance. The oestrogen component of Lizinna may cause a decrease in glucose tolerance, while the progestogens may increase insulin secretion and create insulin resistance. Because of these demonstrated effects, pre-diabetic and diabetic women in particular should be carefully monitored while taking oral contraceptives.
• Asymptomatic gall bladder disease or cholecystectomy.
• Benign liver tumours (focal nodular hyperplasia). There is limited, direct evidence that hormonal contraceptive use does not influence either progression or regression of liver lesions among women with focal nodular hyperplasia.
• Migraine without focal aura. The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent or severe requires discontinuation of oral contraceptives and evaluation of the cause.
• Crohn's disease and ulcerative colitis have been associated with COC use.
If any of the following conditions developed or worsened during a prior pregnancy or during previous COC use, they may occur while taking Lizinna:
• elevated blood pressure
• cholestasis
• herpes gestationis
• otosclerosis
• SLE
• severe headaches
• haemolytic uraemic syndrome
• Sydenham's chorea
• exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema.
Chloasma
Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking this preparation. Chloasma is often not fully reversible.
Additional contraceptive precautions
When additional contraceptive precautions are required, the patient should be advised either not to have sex, or to use a cap plus spermicide or for her partner to use a condom. Rhythm methods should not be advised as the Pill disrupts the usual cyclical changes associated with the natural menstrual cycle, e.g. changes in temperature and cervical mucus.
Excipients
The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Potential Reduction in Contraceptive Effectiveness Associated With Co-Administration of Other Drugs:
Hepatic enzyme inducers
Drugs or herbal products that induce enzymes, especially CYP3A4, may decrease the plasma concentrations of contraceptive hormones, and may decrease their effectiveness and/or increase breakthrough bleeding. Enzyme induction may be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks, but may then be sustained for at least 4 weeks after the cessation of medicinal product therapy.
Examples include:
- barbiturates
- bosentan
- carbamazepine
- eslicarbazepine acetate
- felbamate
- (fos)aprepitant
- hydantoins
- primidone
- griseofulvin
- some (combinations of) HIV protease inhibitors (e.g. nelfinavir, ritonavir, ritonavir-boosted protease inhibitors)
- some HCV protease inhibitors (e.g. boceprevir, telaprevir)
- modafinil
- some non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine)
- oxcarbazepine
- phenytoin
- rifampicin and rifabutin
- rufinamide
- St. John's Wort
- topiramate
Drugs that affect absorption
Drugs that increase gastrointestinal motility, e.g. metoclopramide, may reduce hormone absorption.
Treatment with activated charcoal will compromise absorption of steroid hormones.
Colesevelam, a bile acid sequestrant, given together with a combined oral hormonal contraceptive, has been shown to significantly decrease the AUC of ethinylestradiol. No interaction was seen when the contraceptive was given 4 hours before colesevelam.
Management
Long-term
For women on long-term treatment with drugs and herbal products that interact with hormonal contraception, another reliable, non-hormonal method of contraception is recommended.
Short-term
Women on short-term treatment with drugs and herbal products that interact with hormonal contraception and may decrease plasma levels of contraceptive hormones could have their contraceptive effectiveness reduced. They should be advised to use a barrier contraceptive method (e.g. condoms, diaphragm) in addition to Lizinna as follows:
• Women using liver enzyme-inducing drugs should temporarily use a barrier contraceptive method in addition to Lizinna during the time of concomitant medicinal product administration and for 28 days after their discontinuation.
• In the case of modafinil, use of a barrier contraceptive method should continue for 56 days after discontinuation.
If discontinuation of the concomitant medicinal product occurs in week three or runs beyond the end of the tablets in the strip, the next strip should be started without a break.
Increase in Plasma Hormone Levels Associated With Co-administered Drugs:
• etoricoxib
• some HIV protease inhibitors (e.g. atazanavir, indinavir)
Changes in Plasma Levels of Co-Administered Drugs that may be of Clinical Significance:
Combination hormonal contraceptives may also affect the pharmacokinetics of some other drugs if used concomitantly.
Drugs whose plasma levels may be increased (due to CYP inhibition)
Examples include:
• ciclosporin
• prednisolone
• selegiline
• theophylline
• tizanidine
Drugs whose plasma levels may be decreased (due to induction of glucuronidation)
Examples include:
• lamotrigine
Management
Physicians are advised to consult the labelling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives and the possible need to adjust dosages.
Pharmacodynamic interactions
During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol-containing medications such as combined hormonal contraceptives (CHCs). Additionally, also in patients treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs (see section 4.3).
Therefore, Lizinna users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with these combination drug regimens. Lizinna can be restarted 2 weeks following completion of treatment with these combination drug regimens.
Use during pregnancy
Not indicated during pregnancy. Confirm suspected pregnancy before discontinuing treatment.
The majority of recent studies do not indicate a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when taken inadvertently during early pregnancy.
The increased risk of VTE during the postpartum period should be considered when re-starting Lizinna (see sections 4.2 and 4.4).
Use during lactation
Contraceptive steroids and/or their metabolites may be excreted in breast milk. In addition, combination hormonal contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use Lizinna or other combination hormonal contraceptives but to use other forms of contraception particularly in the first 6 weeks post-partum.
Not applicable.
Description of selected adverse reactions
An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs. These are discussed in more detail in section 4.4.
These adverse drug reactions (ADRs) require immediate medical attention and/or cessation of oral contraceptive use.
The following ADRs may also require immediate medical attention and/or cessation of CHC use: retinal vein thrombosis, new onset of migraine -type headache, breast cancer, hepatic tumours, adenomas, high blood pressure, angioedema, urticaria and hypersensitivity.
Alternative non-hormonal methods of contraception should be used, while appropriate diagnostic and therapeutic measures are undertaken.
Based on pooled safety data from 5 clinical trials, the most commonly reported (≥10%) ADR was headache (27.9%). The most commonly reported (≥10%) ADR identified during post-marketing experience was diarrhoea (11.8%).
The most common ADRs (≥10%) reported in the first treatment cycle in clinical trials were: dysmenorrhoea (40.4%); nausea (29.1%); metrorrhagia (26.3%); gastrointestinal disorder [reported as nausea or vomiting] (24.6%) and abnormal withdrawal bleeding (16.9%). The incidence of these ADRs was highest in cycle 1 and decreased over time with the exception dysmenorrhoea. The highest incidence of vomiting occurred in cycle 12 (11.8%).
The 5 clinical trials (2 randomised active-controlled trials and 3 uncontrolled open-label trials), which were used to evaluate the safety of , included 1,891 healthy women of child bearing potential. In 3 trials, subjects were followed for up to 24 cycles and in the other 2 trials for up to 12 cycles. An additional uncontrolled study (n=8,331) reported ADRs by treatment cycle for up to 24 cycles. As the frequency of ADRs vary according to the cycle of treatment, the highest cycle incidence has been used to assign the ADR to a frequency category.
The table below displays all ADRs that have been reported with the use of Norgestimate / Ethinylestradiol in clinical trials or from post marketing experiences with norgestimate and ethinyl estradiol tablets.
The displayed frequency categories use the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).
Infections and infestations
Common
Urinary tract infection, vaginal infection
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Uncommon
Cervical dysplasia
Rare
Breast cyst
Frequency not known
Hepatic adenomas , breast cancer, benign breast neoplasm, focal nodular hyperplasia, fibroadenoma of breast
Immune system disorders
Common
Hypersensitivity
Metabolism and nutrition disorders
Common
Fluid retention
Uncommon
Increase and decrease in appetite, weight fluctuation
Rare
Appetite disorder
Frequency not known
Dyslipidaemia
Psychiatric disorders
Common
Mood altered, depression, nervousness, insomnia
Uncommon
Anxiety, libido disorder
Nervous system disorders
Very common
Headache
Common
Migraine, dizziness
Uncommon
Syncope, paraesthesia
Frequency not known
Cerebrovascular accident, convulsion
Eye disorders
Uncommon
Visual impairment, dry eye
Frequency not known
Intolerance to contact lenses, retinal vascular thrombosis*
Ear and labyrinth disorders
Rare
Vertigo
Cardiac disorders
Uncommon
Palpitations
Rare
Tachycardia
Frequency not known
Myocardial infarction
Vascular disorders
Uncommon
Thrombosis, hypertension, hot flush
Rare
Venous thromboembolism, Arterial thromboembolism
Frequency not known
Deep venous thrombosis*
Respiratory, thoracic and mediastinal disorders
Uncommon
Dyspnoea
Frequency not known
Pulmonary embolism*
Gastrointestinal disorders
Very common
Gastrointestinal disorder, vomiting, diarrhoea, nausea
Common
Gastrointestinal pain, abdominal pain, abdominal distension, constipation, flatulence
Rare
Pancreatitis
Hepato-biliary disorders
Rare
Hepatitis
Frequency not known
Transaminase increased
Skin and subcutaneous tissue disorders
Common
Acne, rash
Uncommon
Alopecia, hirsutism, urticaria, pruritus, erythema, skin discolouration
Rare
Hyperhidrosis, photosensitivity reaction
Frequency not known
Angioedema, erythema nodosum, night sweats
Musculoskeletal and connective tissue disorders
Common
Muscle spasms, pain in extremity, back pain
Uncommon
Myalgia
Reproductive system and breast disorders
Very common
Dysmenorrhoea, metrorrhagia, abnormal withdrawal bleeding
Common
Amenorrhoea, genital discharge, breast pain
Uncommon
Breast discharge, breast enlargement, ovarian cyst, vulvovaginal dryness
Rare
Vaginal discharge
Frequency not known
Suppressed lactation
General disorders and administration site conditions
Common
Chest pain, oedema, asthenic conditions
Investigations
Common
Weight increased
Uncommon
Weight decreased
* Not seen in clinical trials therefore frequency cannot be estimated. See section 4.4 for frequency based on standard reporting rates for similar combined hormonal contraceptives.
Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema. (Frequency 'unknown')
There have been no reports of serious ill-health from overdose. Symptoms that may occur are nausea, vomiting and vaginal bleeding. There are no antidotes and further treatment should be symptomatic.
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Lizinna 250 microgram /35 microgram Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.